Hillsdale Investment Management Inc. trimmed its position in shares of Humana Inc. (NYSE:HUM) by 0.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,590 shares of the insurance provider’s stock after selling 10 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Humana were worth $383,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Humana by 2,281.7% during the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after purchasing an additional 11,867,056 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Humana by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock worth $2,380,366,000 after purchasing an additional 157,868 shares in the last quarter. FMR LLC increased its position in shares of Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after purchasing an additional 1,479,210 shares in the last quarter. State Street Corp increased its position in shares of Humana by 1.4% during the first quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after purchasing an additional 84,716 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Humana by 1.5% during the second quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock worth $657,157,000 after purchasing an additional 39,400 shares in the last quarter. Hedge funds and other institutional investors own 95.12% of the company’s stock.

WARNING: “Hillsdale Investment Management Inc. Reduces Position in Humana Inc. (HUM)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/hillsdale-investment-management-inc-reduces-position-in-humana-inc-hum/1601139.html.

In other news, insider Elizabeth D. Bierbower sold 9,786 shares of Humana stock in a transaction on Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the completion of the sale, the insider now owns 18,042 shares of the company’s stock, valued at $4,672,878. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the sale, the insider now directly owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,595 shares of company stock valued at $14,133,706. Company insiders own 0.80% of the company’s stock.

Several brokerages recently commented on HUM. UBS AG reiterated a “neutral” rating and set a $237.00 price target (up from $205.00) on shares of Humana in a research report on Wednesday, June 28th. BidaskClub cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, June 13th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $262.00 price target for the company in a research report on Wednesday, June 7th. Royal Bank Of Canada reiterated a “hold” rating and set a $214.00 price target on shares of Humana in a research report on Monday, June 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $246.00 price target on shares of Humana in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $246.60.

Humana Inc. (NYSE:HUM) opened at 243.63 on Friday. The stock has a 50 day moving average price of $250.95 and a 200 day moving average price of $232.23. The firm has a market cap of $35.21 billion, a price-to-earnings ratio of 20.04 and a beta of 0.87. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $259.76.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter in the previous year, the business earned $2.30 earnings per share. Equities research analysts expect that Humana Inc. will post $11.55 EPS for the current year.

The firm also recently disclosed a dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 29th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio is currently 13.06%.

Humana Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.